quantisnow
FeedTopReportsPricing
⌘K
Live feed
15:01:42·73d
SECFiling
Liminatus Pharma Inc. logo

Liminatus Pharma Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits

LIMN· Liminatus Pharma Inc.
Original source

Companies

  • LIMN
    Liminatus Pharma Inc.

Related

  • SEC23d
    SEC Form 10-K filed by Liminatus Pharma Inc.
  • PR38d
    Liminatus Pharma Announces Planned Phase 1 Clinical Trial of IBA101, a Next-Generation CD47 Blocking Antibody
  • SEC50d
    Liminatus Pharma Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits
  • SEC62d
    SEC Form SCHEDULE 13G filed by Liminatus Pharma Inc.
  • SEC64d
    Liminatus Pharma Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits
  • SEC65d
    SEC Form 424B4 filed by Liminatus Pharma Inc.
  • PR66d
    Liminatus Pharma, Inc. Announces Pricing of $4.0 Million Public Offering
  • SEC66d
    SEC Form EFFECT filed by Liminatus Pharma Inc.
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022